Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277854 | 0.94 | SIRT2 (0.48) | SIRT1SIRT2SIRT3HDAC4EP300 | |
| SCHEMBL10075870 | 0.90 | EPHX1 (0.47) | SIRT1SIRT2EPHX1SIRT3SIRT6 | |
| SCHEMBL13311506 | 0.88 | SIRT1 (0.41) | SIRT1SIRT2EPHX1SIRT3HDAC4 | |
| SCHEMBL23758129 | 0.87 | SIRT1 (0.44) | SIRT1SIRT2EPHX1SIRT3SIRT6 | |
| SCHEMBL31644317 | 0.82 | EPHX1 (0.50) | SIRT1SIRT2EPHX1SIRT3SIRT6 | |
| SCHEMBL2607891 | 0.82 | SIRT1 (0.44) | SIRT1SIRT2SIRT3HDAC4EP300 | |
| SCHEMBL13932138 | 0.82 | ACHE (0.44) | SIRT1SIRT2SIRT3 | |
| SCHEMBL12583936 | 0.82 | SIRT1 (0.47) | SIRT1SIRT2SIRT3HDAC4EP300 | |
| SCHEMBL12410205 | 0.82 | SIRT1 (0.49) | SIRT1SIRT2SIRT3HDAC4EP300 | |
| SCHEMBL25176590 | 0.81 | KMT2A (0.45) | SIRT1SIRT2SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249033-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249033-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | SIRT1 3966/4885SIRT2 4162/4885EPHX1 459/4885 |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | SIRT1 3966/4885SIRT2 4162/4885EPHX1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.